These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Barnes K; McIntosh E; Whetton AD; Daley GQ; Bentley J; Baldwin SA Oncogene; 2005 May; 24(20):3257-67. PubMed ID: 15735728 [TBL] [Abstract][Full Text] [Related]
24. IRF8 regulates acid ceramidase expression to mediate apoptosis and suppresses myelogeneous leukemia. Hu X; Yang D; Zimmerman M; Liu F; Yang J; Kannan S; Burchert A; Szulc Z; Bielawska A; Ozato K; Bhalla K; Liu K Cancer Res; 2011 Apr; 71(8):2882-91. PubMed ID: 21487040 [TBL] [Abstract][Full Text] [Related]
25. Targeted chronic myeloid leukemia therapy: seeking a cure. Fausel C J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609 [TBL] [Abstract][Full Text] [Related]
27. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Drexler HG; MacLeod RA; Uphoff CC Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072 [TBL] [Abstract][Full Text] [Related]
28. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463 [TBL] [Abstract][Full Text] [Related]
29. TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation. Uchida E; Suwa S; Yoshimoto R; Watanabe K; Kasama T; Miura O; Fukuda T Int J Oncol; 2019 May; 54(5):1785-1796. PubMed ID: 30864683 [TBL] [Abstract][Full Text] [Related]
30. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280 [TBL] [Abstract][Full Text] [Related]
32. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia. Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504 [TBL] [Abstract][Full Text] [Related]
33. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors. Danisz K; Blasiak J Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759 [TBL] [Abstract][Full Text] [Related]
34. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients. Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635 [TBL] [Abstract][Full Text] [Related]
35. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Bhatia R; Munthe HA; Verfaillie CM Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945 [TBL] [Abstract][Full Text] [Related]
36. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms. Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201 [TBL] [Abstract][Full Text] [Related]
37. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
38. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells. Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859 [TBL] [Abstract][Full Text] [Related]
39. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment. Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481 [TBL] [Abstract][Full Text] [Related]
40. miRNAs in chronic myeloid leukemia: small molecules, essential function. Litwińska Z; Machaliński B Leuk Lymphoma; 2017 Jun; 58(6):1297-1305. PubMed ID: 27736267 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]